Tania Distler

Tania Distler

Auto-generated profile, based on publicly available information

Tania Distler

Global Health Institute, School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL)

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
LMLara Marrone
Lara Marrone
HDHannes C. A. Drexler
Hannes C. A. Drexler
JWJie Wang
Jie Wang
PTPriyanka Tripathi
Priyanka Tripathi
TDTania Distler
Tania Distler
JSJared L. Sterneckert
Jared L. Sterneckert
Amyotrophic lateral sclerosis (ALS) is a lethal disease characterized by motor neuron degeneration and associated with aggregation of nuclear RNA-binding proteins (RBPs), including FUS. How FUS aggregation and neurodegeneration are prevented in healthy motor neurons remain critically unanswered questions. Here, we use a combination of ALS patient autopsy tissue and induced pluripotent stem cell-derived neurons to study the effects of FUS mutations on RBP homeostasis. We show that FUS’ tendency to aggregate is normally buffered by interacting RBPs, but this buffering is lost when FUS mislocalizes to the cytoplasm due to ALS mutations. The presence of aggregation-prone FUS in the cytoplasm causes imbalances in RBP homeostasis that exacerbate neurodegeneration. However, enhancing autophagy using small molecules reduces cytoplasmic FUS, restores RBP homeostasis and rescues motor function in vivo. We conclude that disruption of RBP homeostasis plays a critical role in FUS-ALS and can be treated by stimulating autophagy.

17 August 2021 in Cell Reports Medicine
Verified
Journal Article
Open access
NPNikhil J. Pandya
Nikhil J. Pandya
CWCongwei Wang
Congwei Wang
VCVeronica Costa
Veronica Costa
PLPaul Lopatta
Paul Lopatta
SMSonja Meier
Sonja Meier
RJRavi Jagasia
Ravi Jagasia
Angelman syndrome (AS) is a neurodevelopmental disorder caused by the loss of maternal UBE3A, a ubiquitin protein ligase E3A. Here, we study neurons derived from patients with AS and neurotypical individuals, and reciprocally modulate UBE3A using antisense oligonucleotides. Unbiased proteomics reveal proteins that are regulated by UBE3A in a disease-specific manner, including PEG10, a retrotransposon-derived GAG protein. PEG10 protein increase, but not RNA, is dependent on UBE3A and proteasome function. PEG10 binds to both RNA and ataxia-associated proteins (ATXN2 and ATXN10), localizes to stress granules, and is secreted in extracellular vesicles, modulating vesicle content. Rescue of AS patient-derived neurons by UBE3A reinstatement or PEG10 reduction reveals similarity in transcriptome changes. Overexpression of PEG10 during mouse brain development alters neuronal migration, suggesting that it can affect brain development. These findings imply that PEG10 is a secreted human UBE3A target involved in AS pathophysiology.

25 October 2024 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
LMLucas A. Meirelles
Lucas A. Meirelles
EVEvangelia Vayena
Evangelia Vayena
ADAuriane Debache
Auriane Debache
ESEric Schmidt
Eric Schmidt
TRTamara Rossy
Tamara Rossy
APAlexandre Persat
Alexandre Persat

4 August 2022 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
AEAmy Easton
Amy Easton
MJMarianne L. Jensen
Marianne L. Jensen
CWCongwei Wang
Congwei Wang
PHPeter H. Hagedorn
Peter H. Hagedorn
YLYuwen Li
Yuwen Li
ACAngela M. Cacace
Angela M. Cacace
Tau is a microtubule-associated protein (MAPT, tau) implicated in the pathogenesis of tauopathies, a spectrum of neurodegenerative disorders characterized by accumulation of hyperphosphorylated, aggregated tau. Because tau pathology can be distinct across diseases, a pragmatic therapeutic approach may be to intervene at the level of the tau transcript, as it makes no assumptions to mechanisms of tau toxicity. Here we performed a large library screen of locked-nucleic-acid (LNA)-modified antisense oligonucleotides (ASOs), where careful tiling of the MAPT locus resulted in the identification of hot spots for activity in the 3′ UTR. Further modifications to the LNA design resulted in the generation of ASO-001933, which selectively and potently reduces tau in primary cultures from hTau mice, monkey, and human neurons. ASO-001933 was well tolerated and produced a robust, long-lasting reduction in tau protein in both mouse and cynomolgus monkey brain. In monkey, tau protein reduction was maintained in brain for 20 weeks post injection and corresponded with tau protein reduction in the cerebrospinal fluid (CSF). Our results demonstrate that LNA-ASOs exhibit excellent drug-like properties and sustained efficacy likely translating to infrequent, intrathecal dosing in patients. These data further support the development of LNA-ASOs against tau for the treatment of tauopathies.

26 May 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
TRTamara Rossy
Tamara Rossy
TDTania Distler
Tania Distler
JPJoern Pezoldt
Joern Pezoldt
JKJaemin Kim
Jaemin Kim
LTLorenzo Talà
Lorenzo Talà
APAlexandre Persat
Alexandre Persat
The opportunistic pathogen Pseudomonas aeruginosa causes antibiotic-recalcitrant pneumonia by forming biofilms in the respiratory tract. Despite extensive in vitro experimentation, how P. aeruginosa forms biofilms at the airway mucosa is unresolved. To investigate the process of biofilm formation in realistic conditions, we developed AirGels: 3D, optically-accessible tissue-engineered human lung models that emulate the airway mucosal environment. AirGels recapitulate important factors that mediate host-pathogen interactions including mucus secretion, flow and air-liquid interface, while accommodating high resolution live microscopy. With AirGels, we investigated the contributions of mucus to P. aeruginosa biofilm biogenesis in in vivo -like conditions. We found that P. aeruginosa forms mucus-associated biofilms within hours by contracting luminal mucus early during colonization. Mucus contractions facilitates aggregation, thereby nucleating biofilms. We show that P. aeruginosa actively contracts mucus using retractile filaments called type IV pili. Our results therefore suggest that, while protecting epithelia, mucus constitutes a breeding ground for biofilms.

18 June 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
LMLucas A. Meirelles
Lucas A. Meirelles
AGArpine Grigoryan
Arpine Grigoryan
LBLaure Le Blanc
Laure Le Blanc
DLDavid Liaskos
David Liaskos
EVEvangelia Vayena
Evangelia Vayena
APAlexandre Persat
Alexandre Persat
During chronic infections, host tissues undergo repeated cycles of injury and repair while being exposed to bacterial products. Although many virulence factors trigger immune responses, whether bacterial metabolites alter tissue architecture by disrupting regenerative programs remains largely unexplored. Here, using a primary-cell-derived human lung microtissue model, we show that the redox-active metabolite pyocyanin (PYO), produced by the opportunistic pathogen Pseudomonas aeruginosa , disrupts airway epithelial regeneration and reshapes tissue architecture, amplifying infection. PYO exposure impairs epithelial repair, leading to defects in mucociliary clearance and promoting bacterial growth. Single-cell transcriptomics and imaging reveal that PYO exposure during basal cell differentiation alters epithelial cell-type composition. Keratin-13-rich cells promote the emergence of squamous regions with defective ciliogenesis, resulting in functional defects. After characterizing how PYO remodels the epithelium, we tested how these changes impact bacterial fitness. Using transposon-insertion sequencing and live imaging of infections, we show that these regeneration defects improve the fitness of mutants that tend to form biofilms, a common feature of chronic infections. Together, our results reveal that PYO reshapes regenerative trajectories and tissue architecture in ways that subsequently alter infection outcomes, highlighting the role of secreted metabolites as potential modulators of tissue regeneration during chronic lung infections.